

* Laboratory of Molecular Immunoregulation, Center for Cancer Research, National Cancer Institute at Frederick, National Institutes of Health, Maryland; and
Department of Pharmacology, College of Medicine, University of Illinois, Chicago
Correspondence: Dr. Joost J. Oppenheim, LMI, CCR, NCI at Frederick, Building 560, Room 21-89, Frederick, MD 21702-1201. E-mail: oppenhei{at}mail.ncifcrf.gov
Immature and mature dendritic cells (iDC and mDC, respectively) migrate to different anatomical sites, e.g., sites of antigen (Ag) deposition and secondary lymphoid organs, respectively, to fulfill their roles in the induction of primary, Ag-specific immune responses. The trafficking pattern of iDC and mDC is based on their expression of functional chemotactic receptors and the in vivo sites expressing the corresponding ligands including chemokines and/or classical chemoattractants. In this study, we have evaluated the expression of the formyl peptide receptor like-2 (FPRL2) by human iDC and mDC. We show that iDC respond chemotactically and by Ca2+ mobilization to N-formyl-Met-Leu-Phe and a recently identified synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met (WKYMVm), whereas mDC derived from the same donor only respond to WKYMVm. Furthermore, iDC and mDC express FPRL2 mRNA and protein. As mDC do not express any other members of the human FPR subfamily, FPRL2 expressed by DC must be functional and mediate the effect of WKYMVm on DC. Indeed, treatment of iDC and mDC with WKYMVm induces the internalization of FPRL2. Thus, human myeloid DC express functional FPRL2 and maintain its expression even after maturation, suggesting that the interaction of FPRL2 and its endogenous ligand(s) may be involved in regulating DC trafficking during Ag uptake and processing in the periphery as well as the T cell-stimulating phase of the immune responses.
Key Words: chemotaxis Ca2+ mobilization maturation
This article has been cited by other articles:
![]() |
R. D. Ye, F. Boulay, J. M. Wang, C. Dahlgren, C. Gerard, M. Parmentier, C. N. Serhan, and P. M. Murphy International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family Pharmacol. Rev., June 1, 2009; 61(2): 119 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Devosse, A. Guillabert, N. D'Haene, A. Berton, P. De Nadai, S. Noel, M. Brait, J.-D. Franssen, S. Sozzani, I. Salmon, et al. Formyl Peptide Receptor-Like 2 Is Expressed and Functional in Plasmacytoid Dendritic Cells, Tissue-Specific Macrophage Subpopulations, and Eosinophils J. Immunol., April 15, 2009; 182(8): 4974 - 4984. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Huggins, N. Paschalidis, R. J. Flower, M. Perretti, and F. D'Acquisto Annexin-1-deficient dendritic cells acquire a mature phenotype during differentiation FASEB J, April 1, 2009; 23(4): 985 - 996. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Li, T. Syrovets, S. Paskas, Y. Laumonnier, and T. Simmet Mature Dendritic Cells Express Functional Thrombin Receptors Triggering Chemotaxis and CCL18/Pulmonary and Activation-Regulated Chemokine Induction J. Immunol., July 15, 2008; 181(2): 1215 - 1223. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. El Zein, B. Badran, and E. Sariban VIP differentially activates {beta}2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1 J. Leukoc. Biol., April 1, 2008; 83(4): 972 - 981. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Karlsson, E. Nygren, J. Karlsson, I. Nordstrom, C. Dahlgren, and K. Eriksson Ability of Monocyte-Derived Dendritic Cells To Secrete Oxygen Radicals in Response to Formyl Peptide Receptor Family Agonists Compared to That of Myeloid and Plasmacytoid Dendritic Cells Clin. Vaccine Immunol., March 1, 2007; 14(3): 328 - 330. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-L. Gao, A. Guillabert, J. Hu, Y. Le, E. Urizar, E. Seligman, K. J. Fang, X. Yuan, V. Imbault, D. Communi, et al. F2L, a Peptide Derived from Heme-Binding Protein, Chemoattracts Mouse Neutrophils by Specifically Activating Fpr2, the Low-Affinity N-Formylpeptide Receptor J. Immunol., February 1, 2007; 178(3): 1450 - 1456. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Babbin, W. Y. Lee, C. A. Parkos, L. M. Winfree, A. Akyildiz, M. Perretti, and A. Nusrat Annexin I Regulates SKCO-15 Cell Invasion by Signaling through Formyl Peptide Receptors J. Biol. Chem., July 14, 2006; 281(28): 19588 - 19599. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Kang, H.-Y. Lee, M.-K. Kim, K. S. Park, Y. M. Park, J.-Y. Kwak, and Y.-S. Bae The Synthetic Peptide Trp-Lys-Tyr-Met-Val-D-Met Inhibits Human Monocyte-Derived Dendritic Cell Maturation via Formyl Peptide Receptor and Formyl Peptide Receptor-Like 2 J. Immunol., July 15, 2005; 175(2): 685 - 692. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kurosaka, Q. Chen, F. Yarovinsky, J. J. Oppenheim, and D. Yang Mouse Cathelin-Related Antimicrobial Peptide Chemoattracts Leukocytes Using Formyl Peptide Receptor-Like 1/Mouse Formyl Peptide Receptor-Like 2 as the Receptor and Acts as an Immune Adjuvant J. Immunol., May 15, 2005; 174(10): 6257 - 6265. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Migeotte, E. Riboldi, J.-D. Franssen, F. Gregoire, C. Loison, V. Wittamer, M. Detheux, P. Robberecht, S. Costagliola, G. Vassart, et al. Identification and characterization of an endogenous chemotactic ligand specific for FPRL2 J. Exp. Med., January 3, 2005; 201(1): 83 - 93. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Chen, D. Wade, K. Kurosaka, Z. Y. Wang, J. J. Oppenheim, and D. Yang Temporin A and Related Frog Antimicrobial Peptides Use Formyl Peptide Receptor-Like 1 as a Receptor to Chemoattract Phagocytes J. Immunol., August 15, 2004; 173(4): 2652 - 2659. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. de Paulis, N. Prevete, I. Fiorentino, A. F. Walls, M. Curto, A. Petraroli, V. Castaldo, P. Ceppa, R. Fiocca, and G. Marone Basophils Infiltrate Human Gastric Mucosa at Sites of Helicobacter pylori Infection, and Exhibit Chemotaxis in Response to H. pylori-derived Peptide Hp(2-20) J. Immunol., June 15, 2004; 172(12): 7734 - 7743. [Abstract] [Full Text] [PDF] |
||||